ONCOLYTICS BIOTECH INC (ONCY)
D
Pipeline Grade
Financial Position (from SEC Filings)
$5.5M
Cash & Equivalents
$7.3M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$159M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04445844 | INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | PHASE2 | Active Not Recruiting | 25 |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezoliz... | PHASE2 | Active Not Recruiting | 122 |
| NCT07446322 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S... | PHASE2 | Recruiting | 60 |
| NCT04215146 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncol... | PHASE2 | Active Not Recruiting | 48 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-16 | 8-K | ONCOLYTICS BIOTECH INC (ONCY) (CIK 0001129928) - EX-99.1 | EDGAR |
| 2026-06-02 | 8-K | ONCOLYTICS BIOTECH INC (ONCY) (CIK 0001129928) - 8-K | EDGAR |
| 2026-06-01 | 8-K | ONCOLYTICS BIOTECH INC (ONCY) (CIK 0001129928) - EX-99.1 | EDGAR |
| 2026-05-22 | 8-K | ONCOLYTICS BIOTECH INC (ONCY) (CIK 0001129928) - EX-99.1 | EDGAR |